Chenhe Yi

655 total citations · 1 hit paper
16 papers, 354 citations indexed

About

Chenhe Yi is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Chenhe Yi has authored 16 papers receiving a total of 354 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Surgery and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Chenhe Yi's work include interferon and immune responses (3 papers), Cancer Mechanisms and Therapy (3 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). Chenhe Yi is often cited by papers focused on interferon and immune responses (3 papers), Cancer Mechanisms and Therapy (3 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). Chenhe Yi collaborates with scholars based in China and Belgium. Chenhe Yi's co-authors include Hu‐Liang Jia, Jing Lin, Jinhong Chen, Weiqing Shao, Lirong Chen, Zhifei Lin, Lu Lu, Lun–Xiu Qin, Rui Zhang and Jubo Zhang and has published in prestigious journals such as Hepatology, Scientific Reports and Metabolism.

In The Last Decade

Chenhe Yi

15 papers receiving 351 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti–Programmed Cell Death‐1 in HCC

2021 212 citations Chenhe Yi, Lirong Chen et al. Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chenhe Yi China	8	157	119	111	90	81	16	354
Hiroki Teraoku Japan	13	107 0.7×	116 1.0×	97 0.9×	96 1.1×	73 0.9×	44	352
Wen‐Ping Lin China	13	196 1.2×	65 0.5×	185 1.7×	60 0.7×	91 1.1×	30	388
Ziyu Xun China	11	175 1.1×	72 0.6×	112 1.0×	114 1.3×	55 0.7×	35	340
Diyu Huang China	9	136 0.9×	169 1.4×	123 1.1×	170 1.9×	96 1.2×	27	466
Jiashuo Chao China	9	116 0.7×	74 0.6×	67 0.6×	60 0.7×	41 0.5×	20	255
Zhi-Qiang Meng China	12	213 1.4×	214 1.8×	97 0.9×	62 0.7×	126 1.6×	16	483
Sunyoung S. Lee United States	10	99 0.6×	79 0.7×	112 1.0×	36 0.4×	48 0.6×	43	265
Yuqiang Shan China	9	81 0.5×	178 1.5×	48 0.4×	48 0.5×	112 1.4×	30	359
Yulin Tan China	11	162 1.0×	94 0.8×	47 0.4×	73 0.8×	85 1.0×	29	399
Maria Aurelia Barbera Italy	9	134 0.9×	69 0.6×	104 0.9×	80 0.9×	53 0.7×	19	284

Countries citing papers authored by Chenhe Yi

Since Specialization

Citations

This map shows the geographic impact of Chenhe Yi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chenhe Yi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chenhe Yi more than expected).

Fields of papers citing papers by Chenhe Yi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chenhe Yi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chenhe Yi. The network helps show where Chenhe Yi may publish in the future.

Co-authorship network of co-authors of Chenhe Yi

This figure shows the co-authorship network connecting the top 25 collaborators of Chenhe Yi. A scholar is included among the top collaborators of Chenhe Yi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chenhe Yi. Chenhe Yi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Jing, Ling, Siying Wang, Chenhe Yi, et al.. (2025). PRMT1-mediated modification of H4R3me2a promotes liver cancer progression by enhancing the transcriptional activity of SOX18. Hepatology Communications. 9(4). 1 indexed citations

Zhang, Bo, Yun Gu, Baorui Tao, et al.. (2025). The Significance of CEA Levels Normalization After Neoadjuvant Therapy in Patients With Initially Resectable Colorectal Liver Metastases. Journal of Surgical Research. 313. 403–411. 1 indexed citations

Wang, Xiangyu, Bo Zhang, Yun Gu, et al.. (2025). The prognostic significance of histopathological growth patterns in liver metastases undergoing surgery: a systematic review and meta-analysis. Clinical & Experimental Metastasis. 42(5). 41–41.

Shao, Weiqing, Yitong Li, Xiaochen Ma, et al.. (2024). Inhibition of PCSK9 prevents and alleviates cholesterol gallstones through PPARα-mediated CYP7A1 activation. Metabolism. 152. 155774–155774. 17 indexed citations

Shao, Weiqing, Yitong Li, Xu Zhou, et al.. (2024). Cholesterol suppresses AMFR-mediated PDL1 ubiquitination and degradation in HCC. Molecular and Cellular Biochemistry. 480(3). 1807–1818. 2 indexed citations

Li, Yitong, Weiqing Shao, Xiaochen Ma, et al.. (2024). GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in metabolic dysfunction-associated steatohepatitis livers. Clinical and Molecular Hepatology. 31(2). 409–425. 2 indexed citations

Tao, Baorui, Chenhe Yi, Yue Ma, et al.. (2023). A Novel TGF-β-Related Signature for Predicting Prognosis, Tumor Microenvironment, and Therapeutic Response in Colorectal Cancer. Biochemical Genetics. 62(4). 2999–3029. 8 indexed citations

Shao, Weiqing, Yiran Chen, Zhifei Lin, et al.. (2023). SREBP2 inhibitor betulin sensitizes hepatocellular carcinoma to lenvatinib by inhibiting the mTOR/IL-1β pathway. Acta Biochimica et Biophysica Sinica. 55(9). 1479–1486. 10 indexed citations

Zhang, Bo, Baorui Tao, Chenhe Yi, et al.. (2022). Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma. European Journal of Internal Medicine. 111. 37–46. 7 indexed citations

10.

Yi, Chenhe, et al.. (2022). A novel refined pyroptosis and inflammasome-related genes signature for predicting prognosis and immune microenvironment in pancreatic ductal adenocarcinoma. Scientific Reports. 12(1). 18384–18384. 5 indexed citations

11.

Wang, Yuedi, Bo Wang, Gils Roex, et al.. (2022). Chimeric antigen receptor clustering via cysteines enhances T-cell efficacy against tumor. Cancer Immunology Immunotherapy. 71(11). 2801–2814. 12 indexed citations

12.

Tao, Baorui, Chenhe Yi, Chong Zhang, et al.. (2022). 27‐Hydroxycholesterol promotes metastasis by SULT2A1‐dependent alteration in hepatocellular carcinoma. Cancer Science. 113(8). 2575–2589. 6 indexed citations

13.

Yi, Chenhe, Lirong Chen, Zhifei Lin, et al.. (2021). Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti–Programmed Cell Death‐1 in HCC. Hepatology. 74(5). 2544–2560. 212 indexed citations breakdown →

14.

Chen, Lirong, Chenhe Yi, Wenshuai Li, et al.. (2020). Inhibition of SPATS2 Suppresses Proliferation and Invasion of Hepatocellular Carcinoma Cells through TRIM44-STAT3 Signaling Pathway. Journal of Cancer. 12(1). 89–98. 10 indexed citations

15.

Zhu, Ying, Xiangyu Wang, Yu Zhang, et al.. (2018). Programmed death ligand 1 expression in human intrahepatic cholangiocarcinoma and its association with prognosis and CD8<sup>+</sup> T-cell immune responses. Cancer Management and Research. Volume 10. 4113–4123. 47 indexed citations

16.

Gao, Xiaomei, Ying Zhu, Jianhua Li, et al.. (2018). microRNA-26a induces a mitochondrial apoptosis mediated by p53 through targeting to inhibit Mcl1 in human hepatocellular carcinoma. OncoTargets and Therapy. Volume 11. 2227–2239. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact